Galderma

Galderma is certainly the heavyweight for rosacea treatments and skincare. Rosacea sufferers will be familiar with Metrogel 1% and Oracea as well as their Cetaphil skincare range. More recently Galderma has gained approval for Mirvaso and also has CD5024/Ivermectin in development.

Recent Rosacea Blog Posts

Mirvaso and Soolantra together like best buddies

Galderma is proposing a Stage 4 trial of 188 participants to demonstrate the effectiveness of Mirvaso and Soolantra used together in treating the redness and papules and pustules of rosacea. The trial is looking for rosacea sufferers with between 15 and 70 papules and pustules and also a score of 3 or 4 in the Clinician’s […]

Continue Reading

Oracea and Finacea prescription prices are increasing !

The JAMA Dermatology has just published a summary of the trend in prescription prices from 2009 to 2015. The news is not good. Overall the brand-name prescriptions increased in price FOUR FOLD during this period. Four national chain pharmacies in the West Palm Beach, Florida, area—specifically, Costco, CVS, Sam’s Club, and Walgreens—were initially surveyed in […]

Continue Reading

`Soolantra: a tough topical’ wins marketing award

As rosacea sufferers we are most familiar with the consumer side of medicine – we see our doctor, get a prescription and head to the pharmacy. But behind all that medicine is a commercial enterprise working to secure our prescription (and insurance) dollars. When a new treatment enters the rosacea market, the treatment will need […]

Continue Reading

Soolantra launches as Rosiver in Canada

  Continuing its tradition of launching new prescription products with names unique to Canada, Galderma Canada has announced that the Ivermectin based treatment known as Soolantra in the US will be known as Rosiver in Canada. In Canada, Mirvaso is known as ONRELTEA, and Oracea is known as Apprilon. The full product monograph, including the consumer […]

Continue Reading

Galderma defending against Actavis Generic Mirvaso

Following on from the large trial announcement by Actavis last year, Galderma has started a suit against Actavis to prevent the sale of Generic Mirvaso. Actavis has filed an abbreviated new drug application with the FDA. Galderma is seeking to use a series of patents to block Actavis from marketing their Brimonidine Topical Gel, 0.33%. […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.